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Abstract
Background: Influenza is a contagious disease caused by a pathogenic virus, with outbreaks all over the world and
thousands of hospitalizations and deaths every year. Due to virus antigenic drift and short-lived immune responses, annual
vaccination is required. However, vaccine coverage is incomplete, and improvement in immunization is needed. The
objective of this study is to investigate a novel method for transdermal delivery using metal microneedle arrays (MN) coated
with inactivated influenza virus to determine whether this route is a simpler and safer approach than the conventional
immunization, capable to induce robust immune responses and confer protection against lethal virus challenge.
Methodology/Principal Findings: Inactivated A/Aichi/2/68 (H3N2) influenza virus was coated on metal microneedle arrays
and applied to mice as a vaccine in the caudal dorsal skin area. Substantial antibody titers with hemagglutination inhibition
activity were detected in sera collected two and four weeks after a single vaccine dose. Challenge studies in mice with
56LD50 of mouse adapted Aichi virus demonstrated complete protection. Microneedle vaccination induced a broad
spectrum of immune responses including CD4+ and CD8+ responses in the spleen and draining lymph node, a high
frequency of antigen-secreting cells in the lung and induction of virus-specific memory B-cells. In addition, the use of MN
showed a dose-sparing effect and a strong Th2 bias when compared to an intramuscular (IM) reference immunization.
Conclusions/Significance: The present results show that delivery of inactivated influenza virus through the skin using metal
microneedle arrays induced strong humoral and cellular immune responses capable of conferring protection against virus
challenge as efficiently as intramuscular immunization, which is the standard vaccination route. In view of the convenience
of delivery and the potential for self-administration, vaccine-coated metal microneedles may provide a novel and highly
effective immunization method.
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Introduction
Transdermal delivery of bioactive compounds on the skin has
been used for thousands of years for therapeutic or prophylactic
purposes, and more than one billion patches are now sold annually
for delivery of small molecule drugs [1]. While the skin permits
entry of certain low molecular weight compounds at therapeutic
rates, the skin’s barrier layer of stratum corneum generally blocks
penetration of macromolecules and vaccines. Vaccine delivery to
the skin therefore typically requires the use of a needle; either a
hollow hypodermic needle or a solid bifurcated needle as used for
scarification to administer smallpox vaccine [2,3,4].
Vaccine delivery to the skin is attractive because of the complex
immunologic network that the skin provides [5]. The skin is
extremely dense in innate immune cell populations whose role is to
recognize, uptake and present foreign antigens to T and B cells in
the draining lymph nodes to initiate adaptive immune responses.
These antigen-presenting cells (APCs) include large numbers of
Langerhans cells (LCs), dermal dendritic cells (DCs), macrophages
and monocytes as well as accessory cells such as keratinocytes
[6,7,8,9]. As a result, vaccines administered to the skin have been
shown to require a lower dose and/or generate stronger immune
responses compared to conventional intramuscular or subcutane-
ous injection [5,10].
Although vaccine delivery to the skin is attractive, vaccines are
not usually administered this way in large part because convenient
and reliable methods do not currently exist. Intradermal injection
requires specialized training and is often unreliable [11].
Scarification also requires training and delivers an inefficient and
variable dose [2,3]. Other methods are under investigation,
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sandpaper or other structures [14,15] and application of electrical
or ultrasonic forces [10,16].
In this study, we examine the use of vaccine-coated microneedles
to deliver an inactivated H3N2 influenza vaccine into the skin. These
micron-scale needles can be fabricated using low-cost methods for
inexpensive mass production; prepared in a patch-like format for
simple administration, possibly by patients themselves; and inserted
painlessly across the stratum corneum and into the skin’s epidermis
and dermis to access the resident dendritic cells [17]. The use of
microneedles has the potential of both increasing the immunologic
response by targeting the skin and providing a simple-to-use delivery
system for reliable administration without specialized training.
In this approach, a microneedle array is pressed manually
against the skin and left in place for a few minutes while the
vaccine coating dissolves off within the skin, after which the
microneedles are discarded. In this study, the effectiveness of this
technology was tested in mice after a single immunization of
inactivated H3N2 virus and lethal challenge with a homologous
mouse adapted strain. H3N2 strains are the leading cause of
mortality and hospitalization rates in influenza-associated epidem-
ics [18,19] and improvements in vaccination would therefore have
great health benefits. We hypothesize that microneedle-based
vaccination will provide protective immunity against influenza
with at least equivalent efficacy and improved applicability relative
to current vaccination methods.
Materials and Methods
Microneedle fabrication
Microneedles were fabricated from stainless steel sheets (Trinity
Brand Industries, SS 304, 75 mm thick; McMaster-Carr, Atlanta,
GA) by laser cutting as described before [20]. To deburr and clean
the microneedle edges and to make the tips sharp, microneedles
were electropolished (model no. E399-100, ESMA, IL) in a solution
containing glycerin, ortho-phosphoric acid (85%) and deionized
waterina ratio of6:3:1byvolume(FisherScientific, Fair Lawn,NJ).
The final microneedle geometry was a linear array of five needles
with a needle-to-needle spacing of 1575 mm. Each needle was
700 mm long, measured 170 mmb y5 5mm in cross section at the
base and tapered to a tip with a 5 mm radius of curvature.
Micro-dip-coating
Microneedles were coated using a dip-coating process with a
specially formulated coating solution described before [21,22]
containing 1% (w/v) carboxymethylcellulose sodium salt (low
viscosity, USP grade, Carbo-Mer, San Diego, CA), 0.5% (w/v)
Lutrol F-68 NF (BASF, Mt. Olive, NJ), 15% (w/v) D-(+)-trehalose
dihydrate (Sigma, St. Louis, MO) and 5 mg/ml inactivated A/
Aichi/2/68 (Aichi) virus. In order to reach high coating efficiency,
the virus was concentrated by microfiltration using 300 kDa cut-
off filters (Vivaspin 500, Sartorius Stedim Biotech, Germany).
The coating was performed manually by dip coating using an
apparatus described elsewhere [21], and monitored by a video
camera (DP71, Olympus America, Center Valley, PA) attached to
a microscope (SZX16, Olympus America) (Figure 1A, 1B).
To measure the amount of vaccine coated per row of
microneedles, three rows from each batch of coated microneedles
were submerged into 200 ml of PBS buffer per row for 5 min.
Vaccine dose was determined by measuring the concentration of
protein in the solution as measured by BCA protein assay (Pierce
Biotechnology, ThermoFisher Scientific, Rockford, IL) coupled
with a calibration curve generated using known concentrations of
Aichi virus.
Cells and virus stocks
Madin-Darby canine kidney (MDCK) cells (ATCC CCL 34,
American Type Culture Collection, Manassas, VA) were main-
tained in Dulbecco’s Modified Eagle’s Medium (DMEM)
(Mediatech, Herndon, VA) containing 10% fetal bovine serum
(Hyclone, ThermoFisher Scientific, Rockford, IL). Influenza virus
stocks (Aichi) were prepared and purified as described [23]. The
purity of the virus was determined by SDS PAGE followed by
Coomassie blue staining and electron microscopy [23]. The
hemagglutination (HA) activity was determined using bovine red
blood cells (LAMPIRE Biological Laboratories, Pipersville, PA) as
previously described [24]. For inactivation, the purified virus was
treated with formalin at a final concentration of 0.1% (vol/vol),
Figure 1. Photograph of (A) a single microneedle coated with influenza vaccine and (B) a five-needle array of microneedles shown with a 26 gauge
hypodermic needle. (C) Electron microscopy of Aichi virus, showing a mixture of filamentous and spherical virus particles. The length of filamentous
forms was between 450–500 nm.
doi:10.1371/journal.pone.0004773.g001
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Inactivation of virus was confirmed by plaque assay in MDCK
cells [25].
The mouse-adapted Aichi strain was obtained by passage 8
times in Balb/c mice. The LD50 was determined in the same
mouse strain and the viral titer was determined as mentioned
above.
Electron microscopy
To confirm the quality and purity of the virus preparation,
purified virus was applied to a formvar carbon coated grid for
1 min, and immediately stained with 1% uranyl acetate for 30 s
[26]. Excess stain was removed by filter paper, and the samples
were examined by transmission electron microscopy (Figure 1C).
Immunizations
Female Balb/c mice (Charles River Laboratory, Wilmington,
MA) (11 mice per group, 6–8 weeks old) were immunized once by
microneedle array (MN) or intramuscular (IM) immunization. For
MN delivery, the mice were anesthetized with a ketamine and
xylazine cocktail and the dorsal caudal surface was prepared to
remove hair as described [23]. MN were then manually inserted
into the skin, left in place for 2 min, and then removed.
Immunization with approximately 3 mgo r1 0mg of vaccine was
accomplished by inserting one or three arrays, respectively, of 5
MN, each coated with 2.860.4 mg of vaccine. IM immunization
was carried out by injecting either 3 mgo r1 0mg vaccine suspended
in 50 ml of PBS into the upper quadrant of the gluteal muscle.
Challenge of mice with influenza virus
To determine post-challenge survival rates and immune
responses, 6 mice per group were challenged 2 months after their
immunization by intranasal instillation of 50 ml of virus with
56LD50 (180 p.f.u.) of live mouse adapted Aichi virus and
monitored for 14 days. As a negative control group, we included 6
naı ¨ve mice. A weight loss exceeding 25% in all infected mice was
used as the experimental end-point, and mice reaching this end-
point were euthanized according to IACUC guidelines. The
challenged mice were monitored daily for signs of morbidity (body
weight changes, fever and hunched posture) and mortality.
Measurement of lung viral titers after challenge
To determine the titers of influenza virus in the lungs of
immunized mice after challenge, the remaining five animals of
each group were infected with 56LD50 and were sacrificed on day
4. Naı ¨ve mice and naı ¨ve mice infected with 56LD50 were used as
control groups. Lung homogenates were prepared in DMEM
serum-free medium to assess the viral titers per gram of tissue by
plaque assay as described above.
Sample collection
The animals were bled on days 14 and 28 after immunization
and on day 4 after challenge. Blood was collected from the retro-
orbital plexus with non-heparinized microcapillaries (Fisher
Scientific, Pittsburgh, PA) after systemic anesthesia. Lung
suspensions were prepared by mincing through a cell strainer
(BD Falcon, Chelmsford, MA) and the cells were resuspended in
DMEM. Lung cells were used in enzyme-linked immunospot
(ELISPOT) assays whereas lung supernatants were mixed with the
protease inhibitor phenylmethylsulfonyl fluoride (1 mM) (Sigma,
St. Louis, MO) and stored at 220uC until assayed for viral titers
and antibody-secreting cells. Inguinal lymph nodes and spleens
were processed similarly into single cell suspensions in complete
RPMI 1640 for cytokine determination [26]. All tissue samples
were treated with red blood cell lysis buffer after their initial
processing (Sigma, St. Louis, MO).
Evaluation of humoral immune responses
All sera and lung supernatants were individually collected, and
anti-Aichi specific IgG, IgG1, IgG2a and IgA antibody levels were
determined quantitatively by enzyme-linked immunosorbent assay
(ELISA) as described [26]. Purified mouse IgG, IgG1, IgG2a, IgA
and goat anti-mouse-HRP for ELISA were purchased from
Southern Biotechnology Associates (Birmingham, AL). Optical
density was read at 450 nm.
We determined the hemagglutination inhibition (HAI) titers
based on the WHO protocol [27] as described previously [23].
Heat-inactivated sera were treated with receptor-destroying
neuraminidase (RDE) (Roche Diagnostics, Indianapolis, IN)
overnight at 37uC, heat inactivated for 30 min at 56uC and
incubated with packed chicken RBC for 1 h at 4uC to remove any
cryoglobulins interfering with the agglutination reaction. They
were serially diluted and pre-incubated at room temperature with
4 HA Units/50 ml of Aichi virus for 30 min. An equal volume of
0.5% chicken red blood cells was then added to each well for
30 min incubation at room temperature. The HAI titer was read
as the reciprocal of the highest dilution of serum that conferred
inhibition of hemagglutination. The values were expressed as the
geometric mean+/2standard error of the mean.
Evaluation of systemic cellular immune responses
Spleen and lymph node cells were prepared from mice
euthanized 4 days after challenge with 56LD50 (180 p.f.u.) mouse
adapted virus. Cell suspensions (0.5–1610
6/well) were stimulated in
vitro in the presence of 1 mg/ml nucleoprotein (NP) peptide
stimulants or Aichi virus in complete RPMI medium (cRPMI)
[28]. As NP immunogen we used the H-2
d-restricted NP class I
peptide (TYQRTRALV) and a pool of three H-2
d-restricted class II
peptides (FWRGENGRKTRSAYERMCNILKGK, RLIQNSL-
TIERMVLSAFDERNK, and AVKGVGTMVMELIRMIKR-
GINDRN) [29,30]. Culture supernatants were collected at 12 h,
48 h and 72 h and stored at 280uC until assayed for IFN-c, IL-4
and IL-2 levels, according to the manufacturer’s instructions
(eBioscience, San Diego, CA).
Quantification of anti-Aichi antibody-forming cells and
memory B cells
Virus-specific antibody-secreting cells (ASC) in the spleen and
the lungs were determined by a modification of the ELISPOT
assay [31,32,33]. Briefly, 96-well plates were coated overnight at
4uC with purified inactivated Aichi virus at a final concentration
4 mg/ml. The plates were washed three times with RPMI and
blocked for 2 h with 10% fetal calf serum prior to sample addition.
Splenocyte and lung single cell suspensions collected at 4 days after
challenge (0.5–1610
6/well) in cRPMI were plated directly on
coated blocked plates and were incubated at 37uC for 36 h. Virus-
specific ASC were detected as spots after incubation with goat
anti-mouse IgG horseradish peroxidase (Southern Biotechnology
Associates) and developed with stable diaminobenzidine (Research
Genetics). Samples were enumerated in an ELISPOT reader
(Cellular Technology, Shaker Heights, OH) and the results shown
as the number of ASC per 10
6 cells.
The ELISPOT assay to detect memory B cells was carried out
similarly, except that splenocytes were stimulated to induce
differentiation of memory B cells into ASC. Cell suspensions
(5610
5/well) were incubated for 1 and 6 days at 37uC in cRPMI
Transdermal Vaccination
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conditioned medium (ConA media) [34] with or without 1 mg/ml
Aichi virus. At the end of the incubation, the cells were washed
twice with complete medium and transferred into virus-coated
plates as described above. To estimate the number of influenza-
specific memory B cells, the number obtained from unstimulated
samples (negative control) was subtracted from those in the
influenza-stimulated samples. ASC numbers of vaccinated mice on
day 1 or day 6 were considered positive if the numbers of spots
were higher than the sum of naı ¨ve infected group ASC numbers
plus 3 times the standard deviation [35].
Statistics
The statistical significance of the difference was calculated by
two-tailed unpaired Student’s t-test and one-way ANOVA (one–
way analysis of variance including Bonferronis’s multiple compar-
ison test). Values were considered significant for p#0.05. Unless
otherwise stated, experiments were run at least in duplicates.
Results
Induction of hemagglutination inhibition and antibody
responses after microneedle immunization with
inactivated influenza virus
To evaluate the efficacy of transdermal immunization with whole
inactivated A/Aichi/2/68 (Aichi) H3N2 influenza virus, we
determined the hemagglutination inhibition (HAI) titers as
correlates of immunity in the sera of immunized mice. Groups of
mice were immunized on the caudal site of the dorsal skin using
solid microneedle arrays (MN) coated with 3 or 10 mg of inactivated
virus (Figure 1). In parallel we immunized mice intramuscularly
(IM) with the same doses of the virus to be used for comparison. We
bled the animals at 14 days and 28 days after a single immunization
and assessed HAI titers in the sera. After immunization at the lower
dose (3 mg), we observed a marked increase in the HAI titers of the
MN group, close to 80, which remained elevated at 28 days
(Figure 2A). Comparable responses were observed with IM
immunization using the same virus dose (Figure 2A). When a
higher antigen dose (10 mg) was used, the HAI titers increased
relative to the lower dose, but were only statistically higher for the
MN group at day 28 (titer: 187, p=0.0035)(Figure 2B). Moreover,
titers in the MN group were significantly higher than the IM group
at the 10 mg dose at day 28. These results demonstrate that a single
MN immunization with inactivated influenza virus induces high
titers of functional antibodies at levels at least comparable to those
observed by IM injection.
We also measured the circulating levels of influenza-specific IgG
in sera by ELISA (Fig. 3). We observed a substantial increase in
influenza virus-specific IgG levels 14 days after immunization in
the sera of immunized mice as compared to the naı ¨ve group
(p,0.001) (Figure 3A). By day 28, the anti-Aichi antibody titers
further increased twofold in the immunized mice with the
exception of the 3 mg IM immunized group. We only observed
a dose-dependent increase in response for the IM group. The high
IgG titers obtained by MN delivery at both doses suggest that it
performs better than IM injection at low doses.
Finally, we examined if the route of immunization influenced
the isotype profile. We found that the IM-immunized groups on
day 14 after immunization exhibited IgG1/IgG2a ratios of 2 and
0.3 with 3 mg and 10 mg inactivated virus, respectively (Figure 3B,
D). In contrast, the MN-immunized groups had IgG1/IgG2a
ratios of 24 and 4 in the 3 mg and 10 mg groups, respectively. By
day 28, there were small increases in the IgG1/IgG2a ratios in all
groups, but the trends were unchanged (Figure 3C, D). This is
significant because the ratio of IgG1/IgG2a is correlated with
immune responses that are predominantly T helper type 2 (Th2)
or T helper type 1 (Th1), suggesting a strong bias towards Th2
responses with the MN route and Th1 with the IM route. This
observation indicates a significant difference in the nature of the
immune response generated using MN delivery to the skin as
opposed to IM injection.
Body weight changes, survival rates and effective
clearance of virus from lungs of challenged mice
The efficacy of a successful vaccine is shown by the protection
induced against lethal challenge with the homologous virus. Mice
from both IM and MN groups were challenged with 56LD50 of
homologous, highly pathogenic mouse-adapted virus 2 months
after immunization. All vaccinated mice survived challenge and
lost less than 10% of their original body weight (Figure 4A, B),
while the naı ¨ve counterparts died within 8 days after challenge.
To further evaluate the protective response, we also examined
the extent to which MN-induced immune responses controlled
viral replication in the lungs in vivo. The unimmunized infected
Figure 2. Influenza-specific hemagglutination inhibition (HAI)
titers. HAI titers of sera from mice immunized with (A) 3 mg and (B)
10 mg inactivated influenza virus administered by intramuscular (IM)
and microneedle (MN) routes of delivery compared to naı ¨ve (N) mice at
14 and 28 days after a single immunization (graphs express
average6s.e)
ap,0.05 when MN 10 mg is compared to the IM 10 mg
group.
doi:10.1371/journal.pone.0004773.g002
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contrast, groups of immunized mice showed at least a 5-log10
decrease in viral titers when compared to the naı ¨ve group
(Figure 4C). Notably, we could not detect any virus in the lungs of
either the MN or IM group at 10 mg. The 3 mg MN and IM
groups had minimal levels of virus on day 4 (4-log10 lower than the
naı ¨ve group) showing that even at this lower vaccination dose the
mice effectively cleared almost all the virus. These data indicate
that MN immunization with inactivated influenza virus can
successfully prevent viral replication and confer protection against
lethal viral challenge similarly to IM injection.
Recall humoral immune responses in challenged mice
Because induction of neutralizing antibodies is a significant
factor in protection from homologous viral challenge, we
compared the humoral immune responses responsible for the
rapid virus clearance. Immunized groups of mice challenged with
56LD50 of mouse adapted Aichi virus 2 months after immuni-
zation demonstrated robust humoral responses that increased with
dose (p=0.015 when comparing 10 mgI Mv s3 mg IM, and
p=0.0017 for 10 mgM Nv s3mg MN respectively), but showed no
significant differences between the IM or MN immunizations
(Figure 5A). The post-challenge HAI titers demonstrated similar
Figure 3. Total anti-influenza serum IgG and isotype profiles after intramuscular (IM) and microneedle (MN) immunization with
3 mgo r1 0mg of inactivated influenza virus compared to naı ¨ve control group (N). (A) Total serum IgG titers determined on days 14 and 28
after immunization. (B) Serum IgG2a and IgG1 isotypes on day 14 and (C) Serum IgG2a and IgG1 isotypes on day 28. (D) Ratio of IgG1/IgG2a on day
14 (E) Ratio of IgG1/IgG2a on day 28. All IgG measurements were made by quantitative ELISA (average6s.e)
ap,0.05 when IM 10 mg compared to the
IM 3 mg group.
doi:10.1371/journal.pone.0004773.g003
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(Figure 5B). The isotype profiles were similar to the pre-challenge
data, maintaining the observed skewed responses toward Th2 for
the MN immunization and Th1 for the IM immunization
(Figure 5C, D).
In vitro cytokine responses
To assess cellular immune responses, we re-stimulated the
splenocytes and lymph node cultures (LN) isolated from
challenged mice on day 4 with NP Class I and II restricted
peptides, and quantified their ability to produce cytokines (IL-2,
IL-4, IFN-c) by ELISA (Figure 6). The production of IL-2 did not
show significant differences in splenocyte or LN cultures re-
stimulated with Aichi virus or NP Class I and II peptides (data not
shown).
In both splenocytes and LN cultures the IL-4 levels did not show
any significant differences between immunized or unimmunized
infected groups after NP Class II re-stimulation (data not shown).
In contrast, after NP Class I re-stimulation, both cell populations
showed a dose-dependent increase in IL-4 production. LN IL-4
responses increased significantly for both the MN (p=0.06) and
the IM groups (p=0.0005). Particularly, the 10 mg MN group
produced a two fold higher level of IL-4 after re-stimulation when
compared to the 10 mg IM group (p=0.0189) (Figure 6A).
Elevated IL-4 production after MN vaccination is consistent with
the heightened Th2 driven responses as indicated by the elevated
IgG1/IgG2a ratio observed in the MN groups, since IL-4
production is associated with class switching [36].
IFN-c levels did not significantly change in splenocyte cultures
of any groups after NP Class I or NP Class II re-stimulation
(Figure 6B, C). However, LN cells re-stimulated with NP Class I
peptides produced a dose-dependent IFN-c secretion that was
independent of the route of vaccination (Figure 6B). NP Class II
peptide-stimulated LN cultures showed a greater increase in IFN-c
response in the IM immunized group compared to the MN
counterpart at the high antigen dose (p,0.05). Elevated IFN-c
production after IM vaccination is consistent with the heightened
Th1-like response indicated by the reduced IgG1/IgG2a ratio in
the IM groups, since IFN-c production is associated with IgG2a
production [37].
Virus-specific antibody secreting cells in immunized mice
The sustained humoral immune responses that confer protec-
tion against influenza infection are attributed in part to long-lived
antibody-secreting cells (ASC). Eight weeks after the immunization
and shortly after challenge, the mice were examined for ASC in
spleen and lungs. In spleen, anti-Aichi IgG ASC were only
elevated in MN and IM groups which received the 10 mg dose,
with no significant differences among these groups. Antigen-
secreting cell numbers were very low in all other groups including
immunized, naı ¨ve or infected mice (Figure 7A).
In contrast, virus-specific IgG ASC in the lungs were elevated in
the MN groups at both antigen doses and in the IM group at high
antigen dose, reflective of the site of infection. Importantly, the
MN 3 mg group had 4-fold higher numbers than the IM group at
Figure 4. Protective efficacy from influenza virus challenge.
Post-challenge survival rates of immunized and control mice were
monitored for 14 days. (A) Percent survival after challenge with 56LD50
with mouse adapted Aichi virus of intramuscularly (IM) or microneedle
array (MN) immunized mice (B) Normalized body weights (BW) of
surviving mice recorded during the infection period. (C) Lung viral titers
were assessed as an indicator of protection after intranasal challenge
with 56LD50 of live Aichi virus, (average6s.e). Lungs were harvested on
day 4 and lung extracts were used to determine viral titers by plaque
assay using MDCK cells. (Inf.) unimmunized infected mice ND: not
detected.
doi:10.1371/journal.pone.0004773.g004
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generation of local humoral responses by MN vaccination.
Induction of memory B cell responses by microneedle
immunization
In contrast to the non-dividing, terminally differentiated ASC,
which spontaneously secrete large antibody amounts without any
antigenic stimulation ex vivo, memory B cells need antigenic
stimulation to divide and differentiate into ASC [35]. Memory B
cells are highly specialized cells that are induced by minimal
amounts of antigen to become antibody-secreting cells conferring
long-term protection [38] and hence important to vaccine
development. To determine whether MN vaccination could result
in the induction of virus-specific B cell memory, splenocytes were
isolated from vaccinated or naı ¨ve mice after challenge with live
mouse-adapted virus. The cells were stimulated with Aichi virus
and used to identify Aichi-specific ASC by ELISPOT assay.
We observed a significant increase in memory B cells over a
period of 6 days (Fig. 8), whereas these numbers were very low in
the control groups supplemented with Con-A conditioned medium
alone (Figure 8). On day 6, all groups presented increased ASC
numbers by 2 to 10 fold when compared to day 1, including the
unimmunized infected mice. We detected a 2-fold higher increase
in the ASC numbers of mice immunized with 3 mg of virus as
compared to the naı ¨ve infected mice and marked 2- to 3-fold
increases in the 10 mg IM and MN groups. These data indicate
that increased vaccine doses correlated with increased numbers of
memory B cells. The similarity in memory B cell numbers
observed after IM and MN immunization demonstrates that MN
immunization was as effective as IM in inducing memory B cell
responses.
Discussion
This study was motivated by the need to improve immunization
against influenza specifically and other diseases in general. Our
main goal was to determine if MN delivery of influenza vaccine
could induce comparable immune responses to the conventional
IM injection, using a MN array with numerous logistical
advantages. We conclude that MN immunization can indeed
provide protective immunity at least as strong as that of IM
injection, with the notable difference that MN vaccination shifted
the immune response significantly toward a Th2 bias.
More specifically, this study showed that vaccination by the new
technology of vaccine-coated MN arrays could induce strong
humoral and cellular immune responses that can effectively confer
full protection with a single immunization. Solid metal MN coated
with inactivated influenza virus conferred 100% protection against
lethal viral challenge and induced short-lived antigen-secreting
cells in the lungs and spleens of immunized mice as well as anti-
influenza memory B cell responses. MN immunization was found
to be at least as effective as the conventional IM route in eliciting
similar levels of functional antibodies at low or high antigen
concentrations, in clearing the virus from the lungs of infected
mice, in conferring protection and in inducing short-lived as well
as memory B immune responses as seen by the frequency of
antigen-secreting cells in spleens of challenged mice. Other
approaches for transdermal and intradermal immunization have
also been recently reported [4,12,13,39,40,41].
Interestingly, we observed differences in the responses between
IM and MN immunization that may have implications for vaccine
development. In IM immunization, the serum IgG responses were
dose related and the Th1 responses were predominant as shown
Figure 5. Humoral immune responses 4 days after challenge. (A) Total serum IgG titers determined with quantitative ELISA and (B) (B) HAI
titers of sera from immunized mice. (C,D) IgG2a and IgG1 isotype titers were determined with quantitative ELISA (average6s.e). (N) Naı ¨ve control,
(Inf.) unimmunized infected mice
ap,0.05 when IM 10 mg is compared to the IM 3 mg group.
bp,0.05 when MN 10 mg is compared to the MN 3 mg
group.
doi:10.1371/journal.pone.0004773.g005
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data. In contrast, responses to MN immunization were similar to
each other at both antigen concentrations and both doses were
equally potent in inducing similar influenza-specific IgG titers. In
addition the transdermal delivery with MN induced robust Th2
responses as seen by the IgG1/IgG2a ratios.
Delivery of antigen into the skin by MN, which are inserted into
the epidermis and the upper layer of the dermis, may activate both
LC and dermal dendritic cells(DCs) which in turn convey the antigen
to the draining lymph nodes [1]. Recent studies have demonstrated
Figure 6. IL-4 and IFN-c secretion by T cells in response to
inactivated influenza antigen. The frequency of cellular immune
responses is shown in immunized and challenged mice. Spleens and
lymph nodes from all groups of immunized mice were individually
processed and cells were cultured in the presence of NP Class I or NP
Class II peptides for stimulation. (A) Splenocytes and lymphocytes were
stimulated with NP Class I peptide and analyzed with ELISA for IL-4
production at 72 hours. Splenocytes and lymphocytes cultured in the
presence of NP Class I (B) or NP Class II stimulants (C) were analyzed for
IFN-c production at 72 hours after stimulation. (N) Naı ¨ve control, (Inf.)
unimmunized infected mice (average6s.e). ND: not detected.
ap,0.05
when MN 10 mg compared to the IM 10 mg group.
bp,0.05 when IM
10 mg compared to the MN 10 mg group.
doi:10.1371/journal.pone.0004773.g006
Figure 7. Antibody secreting cells (ASC) in spleens and lungs of
immunized mice. (A) Splenocytes and (B) single cell suspensions from
lungs of immunized mice were assessed by ELISPOT assay for anti-
influenza IgG ASC and compared with (N) naı ¨ve control, and (Inf.)
unimmunized infected groups 4 days post–challenge (average6s.e).
ap,0.05 when MN 3 mg compared to the IM 3 mg group.
bp,0.05
when MN 10 mg compared to the IM 3 mg group.
doi:10.1371/journal.pone.0004773.g007
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in controlling the adaptive immune response [42,43]. In this study,
we observed that MN immunization successfully elicited Th1 and
Th2 responses with a single dose. Interestingly, the cellular and
humoral responses generated using the transdermal route were
skewed predominantly to Th2 when compared to IM, likely a
consequence of higher levels of IL-4 secretion from spleen and
inguinal lymph nodes. Although IL-4 secretion was seen by both
CD4+ and CD8+ T cell lymphocytes, the differences in IL-4 levels
were mainly attributed to the CD8+ population as seen by the NP
Class I stimulation of lymphocytes, because neither polyclonal
stimulation with inactivated Aichi virus nor the presence of NP Class
II peptides revealed any distinct differences among immunized
groups. The levels of CD4+ associated IFN-c were similar in both
spleens and lymph nodes of IM and MN groups whereas the CD8+
associatedIFN-cwashigherinthelymphocytesoftheIMimmunized
animals. The generation of a broad spectrum of T cell responses and
the differences observed by the administration route deserve further
consideration since recent reports have demonstrated the importance
of T cell memory responses in heterologous protection, especially in
influenza cases of antibody-escape variants [44,45].
It has been reported that elderly people, who face higher risk
from influenza infection, have decreased IL-2 production,
diminished cytotoxic T-lymphocyte (CTL) activity [46,47,48]
and changes in T helper cell memory affecting the Th1 responses
to influenza infection [49]. Achieving the most effective immune
response against influenza may require an optimal balance of Th1
and Th2 responses. The development of a strategy that
incorporates the use of adjuvants in MN delivery may enable this
balance to be achieved.
The induction of ASC in the lungs, which are the site of virus
entry and replication, is important to maintain sustained immune
responses after vaccination. We found that both concentrations of
antigen delivered with MN induced the same numbers of ASC in
the lung, whereas the 3 mg IM induced lower levels of these cells.
Although we did not observe any significant IgA levels in the
mucosa (data not shown), It is likely that one immunization is not
sufficient to induce high IgA titers.
In addition to the immunologic similarities and differences
between MN and IM delivery, the use of MN presents several
logistic advantages for vaccination. First, MN inherently delivers
antigen to the APC in the skin by targeting mainly the epidermis
and the upper layers of dermis. This approach may provide dose
sparing as suggested by data shown in this study as well as previous
studies [50,51]. Influenza vaccine production capacity has limited
access to seasonal vaccine in some recent years and, in the event of
a future influenza pandemic, vaccine supply will almost certainly
be insufficient [52]. Thus, dose-sparing approaches are important
to ensuring an adequate supply of influenza vaccine.
Another advantage of MN-based delivery is the simplicity of
MN administration compared to hypodermic injection. MN arrays
can be integrated into patches that can be applied by manual
pressing against the skin. Such MN patches are envisioned to
require no special training and can be suitable for administration
by minimally trained personnel or by patients themselves.
Microneedles have also been shown to be painless in contrast to
hypodermic needles [53]. These features of microneedles could
increase coverage of seasonal and pandemic influenza vaccination
by facilitating school-based vaccination of children, self-adminis-
tration by busy adults, and easy access to vaccination in elder-care
facilities or at home, which would minimize risks of long delays
associated with injection-based vaccination at centralized clinics.
This contrasts with the specialized training needed for IM
hypodermic injection and the even more specialized training,
and noted unreliability, of intradermal hypodermic injection [11].
Other advantages include the small package size of MN, which
reduces storage, transportation and disposal volumes and
associated costs. A MN patch is small enough to fit inside an
envelope for delivery by the postal service and will occupy much
less space in the cold chain, of critical importance in developing
countries. MN should reduce the dangers of accidental and
intentional hypodermic needle re-use and thereby increase safety.
Coating MN with a dry vaccine formulation that inherently avoids
the need for reconstitution should prolong their shelf life and
resistance to elevated temperatures. When mass-produced, MN
are expected to have a cost similar to that of a conventional
hypodermic needle and syringe [17]. Solid metal MN delivery
offers the potential to increase the vaccine coverage not only for
prevention of influenza, but also for other infectious diseases.
Future MN immunization studies are warranted in other animal
models including guinea pigs, pigs or ferrets, whose skin thickness
is closer to that of human skin. Additional dose-response studies
are needed to define the minimum antigen dose that will confer
full protection against lethal viral infection. Challenge studies with
higher LD50 levels will also provide further insight into the potency
of MN immunization to induce protection. Another very
important topic for future study is to determine the potential of
MN immunization to enhance the breadth of immunity against
homologous and heterologous influenza strains.
Acknowledgments
We thank Ms. Erin-Joi Collins for excellent assistance with manuscript
preparation.
Author Contributions
Conceived and designed the experiments: DGK MdPM VGZ RC MRP
IS. Performed the experiments: DGK MdPM VGZ SPS IS. Analyzed the
data: DGK IS. Contributed reagents/materials/analysis tools: RC MRP.
Wrote the paper: DGK MdPM RC MRP IS.
Figure 8. Induction of anti-influenza-specific IgG memory B
cells in spleens of immunized mice. Splenocytes were stimulated
with inactivated whole virus for 6 days in the presence of ConA medium
to assess the generation of anti-influenza IgG memory B cell by
ELISPOT, (average6s.e). ConA (d1): ASC cells stimulated with ConA
medium and enumerated on day 1.Virus+ConA (d1): memory B cells
stimulated with influenza virus as an antigen and ConA medium and
enumerated on day 1. Virus+ConA (d6): memory B cells stimulated with
influenza virus and ConA medium and enumerated on day 6.
doi:10.1371/journal.pone.0004773.g008
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